Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Dec 22, 2016 12:19pm
123 Views
Post# 25635641

RE:RE:RE:RE:RE:RE:RE:Can't log in at agoracom...

RE:RE:RE:RE:RE:RE:RE:Can't log in at agoracom...Hi Jkj. Great post!

Yes I do remember your posts and keep them coming. I was surprise by the number of people who flammed
me and felt his compensation was commiserate with other CEO's. Perhaps those other CEOs have had demonstrated successes?

Either way, after the updates from Jan and Feb 2016 (when I started to feel hosed) and Dec15th 2016 where
I really feel hosed I feel more strongly than even that Don's compensation package must change.

But you are right, Don controls both boards and managements and things will not change. KD has him where
he wants him until such a time that Don actually has a success or KD wants him out.

Mind you he did appoint Norma Biln as an independent board member this year and she seems to bring some
valuable credentials.

Who knows? Not me. Ultimately this will be driven by the science. The next licensing deal, if and when it ever
gets done, will speak volumes about the corporate strategy as well as the science.

Great post Jkj. Keep em commin!
Cheers
Toinv



Bullboard Posts